These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [Treatment of advanced prostatic carcinoma with a depot LH-RH analog (ICI 118630)]. Grifoni R; Pierangeli T Minerva Urol Nefrol; 1989; 41(1):5-10. PubMed ID: 2527415 [TBL] [Abstract][Full Text] [Related]
4. Buserelin treatment of advanced prostatic cancer: a phase II study. Veronesi A; Lo Re G; Dal Bo V; Magri MD; Della Valentina M; Talamini R; Merlo A; Francini M; Monfardini S Med Oncol Tumor Pharmacother; 1989; 6(4):255-7. PubMed ID: 2515400 [TBL] [Abstract][Full Text] [Related]
5. Long term follow-up of patients with advanced prostatic cancer treated with nasal buserelin. Falkson CI; Falkson G; Falkson HC Ann Oncol; 1991 Apr; 2(4):303-4. PubMed ID: 1907843 [TBL] [Abstract][Full Text] [Related]
6. Buserelin in the treatment of prostatic cancer. Roila F Biomed Pharmacother; 1989; 43(4):279-85. PubMed ID: 2506941 [TBL] [Abstract][Full Text] [Related]
7. A long term follow-up of patients with advanced prostatic cancer treated with buserelin. Waxman JH; Hendry WF; Whitfield HN; Oliver RT Prog Clin Biol Res; 1985; 185A():271-7. PubMed ID: 3929266 [TBL] [Abstract][Full Text] [Related]
8. Serum prolactin levels in patients treated with a gonadotropin-releasing hormone analogue for adenocarcinoma of the prostate. Siegel YI; Korczak D; Lindner A Eur Urol; 1991; 19(1):16-8. PubMed ID: 1901042 [TBL] [Abstract][Full Text] [Related]
9. Treatment of advanced prostatic cancer with buserelin, an analogue of gonadotrophin releasing hormone. Waxman JH; Wass JA; Hendry WF; Whitfield HN; Bary P; Besser GM; Malpas JS; Oliver RT Br J Urol; 1983 Dec; 55(6):737-42. PubMed ID: 6418264 [TBL] [Abstract][Full Text] [Related]
10. [1st clinical results of the treatment of locally advanced prostatic cancer with a powerful LH-RH analog: buserelin acetate]. Nagel R; Borgmann V; Al-Abadi H; Schmidt-Gollwitzer M J Urol (Paris); 1983; 89(9):669-76. PubMed ID: 6425419 [TBL] [Abstract][Full Text] [Related]
11. Duration of testosterone suppression after a 9.45 mg implant of the GnRH-analogue buserelin in patients with localised carcinoma of the prostate a 12-month follow-up study. Pettersson B; Varenhorst E; Petas A; Sandow J Eur Urol; 2006 Sep; 50(3):483-9. PubMed ID: 16626856 [TBL] [Abstract][Full Text] [Related]
12. Long-term results with the Gn-RH analogue, buserelin, in metastatic prostate cancer. Maffezzini M; Villa E; Broglia L; Francesca F; Rigatti P Tumori; 1990 Feb; 76(1):66-8. PubMed ID: 2108517 [TBL] [Abstract][Full Text] [Related]
13. Advanced male breast cancer treatment with the LH-RH analogue buserelin alone or in combination with the antiandrogen flutamide. Doberauer C; Niederle N; Schmidt CG Cancer; 1988 Aug; 62(3):474-8. PubMed ID: 3134119 [TBL] [Abstract][Full Text] [Related]
14. Dramatic response of pulmonary metastasis from prostatic cancer to LH-RH agonist treatment. Heyman J; Leiter E Mt Sinai J Med; 1989 Mar; 56(2):108-10. PubMed ID: 2501670 [TBL] [Abstract][Full Text] [Related]
15. Clinical importance of prostatic measurements in follow-up of GnRH analogue-treated prostatic carcinoma patients. Matzkin H; Greenstein A; Braf Z Urology; 1990 Sep; 36(3):214-8. PubMed ID: 2118285 [TBL] [Abstract][Full Text] [Related]
16. Results of a Dutch trial with the LHRH agonist buserelin in patients with metastatic prostatic cancer and results of EORTC studies in prostatic cancer. Debruyne FM Am J Clin Oncol; 1988; 11 Suppl 1():S33-5. PubMed ID: 2968760 [TBL] [Abstract][Full Text] [Related]
17. Response of circulating gonadotropin levels to GnRH agonist treatment in prostatic cancer. Huhtaniemi I; Venho P; Jacobi G; Rannikko S J Androl; 1991; 12(1):46-53. PubMed ID: 1901309 [TBL] [Abstract][Full Text] [Related]